Sopharma AD-Sofia's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 55.9.
Sopharma AD-Sofia's Days Inventory for the
three
months ended in Mar. 2026 was 91.02.
Sopharma AD-Sofia's Days Payable for the
three
months ended in Mar. 2026 was 60.76.
Therefore, Sopharma AD-Sofia's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 86.16.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Sopharma AD-Sofia Cash Conversion Cycle Related Terms
Sopharma AD-Sofia Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Sopharma AD-Sofia's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a Cash Conversion Cycle of 86.16 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Cash Conversion Cycle too high?
Sopharma AD-Sofia's current Cash Conversion Cycle is 86.16. The Medical Distribution industry median Cash Conversion Cycle is 55.95. Sopharma AD-Sofia's value of 86.16 is 54% above this industry median. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Cash Conversion Cycle compare to MCK and CAH?
Sopharma AD-Sofia's Cash Conversion Cycle of 86.16 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 55.95. Sopharma AD-Sofia's value of 86.16 is 54% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 55.95, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Cash Conversion Cycle of 86.16 is 54% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 55.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Cash Conversion Cycle is 86.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.52, compared to a current price of zł7.70 — trading 43% below its estimated fair value. The current Cash Conversion Cycle is 86.16 and 54% above the Medical Distribution industry median of 55.95. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Cash Conversion Cycle is 86.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.70 is trading 43% below its estimated GF Value™ of zł13.52.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Cash Conversion Cycle: 86.16
GF Value™: zł13.52 vs. price of zł7.70 (43% below fair value)
Industry Position: 54% above the Medical Distribution median
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
